Internal Medicine, Hematology & Oncology · Camp Hill, PA
NPI
1902854904
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3912 Trindle Rd
Camp Hill, PA, 17011
Phone (717) 761-8740
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.9M
100,975 services
Medicare patients, 2024
510
Average age 75
Drug cost, 2024
$6.5M
1,171 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajesh Surapaneni was code J0897 (injection, denosumab, 1 mg), 9,240 times for 51 patients. In total Rajesh Surapaneni billed 100,975 services in 126 codes, and Medicare paid $1.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2015-06-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 9,240 | 51 | $20.49 | $189K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,550 | 15 | $6.25 | $16K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,700 | 17 | $16.17 | $27K |
| 85025 Blood Count | Office | 806 | 329 | $7.52 | $6,064 |
| 36415 Venipuncture Blood Collection | Office | 788 | 359 | $7.01 | $5,520 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 770 | 21 | $0.09 | $66.6 |
| 80053 Clinical Chemistry | Office | 480 | 219 | $10.25 | $4,921 |
| 99214 Office E&M - Established | Office | 463 | 246 | $86.70 | $40K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 320 | 12 | $0.73 | $233 |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 312 | 14 | $109.47 | $34K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 280 | 11 | $0.07 | $20.93 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 258 | 95 | $0.51 | $131 |
| 96372 Injection Administration | Office | 240 | 96 | $10.21 | $2,449 |
| 96413 Chemotherapy Administration | Office | 191 | 47 | $88.50 | $17K |
| 96375 Injection Administration | Office | 146 | 37 | $10.91 | $1,592 |
By year: 2022 $1.9M for 118,325 services; 2023 $1.6M for 102,524 services; 2024 $1.9M for 100,975 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 806 | 329 | $7.52 | $6,064 |
| 36415 Venipuncture Blood Collection | 788 | 359 | $7.01 | $5,520 |
| 80053 Clinical Chemistry | 480 | 219 | $10.25 | $4,921 |
| 83540 Clinical Chemistry | 142 | 105 | $6.34 | $900 |
| 83550 Clinical Chemistry | 141 | 105 | $8.57 | $1,208 |
| 82728 Clinical Chemistry | 141 | 105 | $13.36 | $1,884 |
| 83615 Clinical Chemistry | 99 | 75 | $5.87 | $581 |
| 82310 Clinical Chemistry | 50 | 36 | $5.06 | $253 |
| 84100 Clinical Chemistry | 46 | 21 | $4.56 | $210 |
| 83735 Clinical Chemistry | 39 | 19 | $6.43 | $251 |
Medicare prescription drug claims, 2024
In 2024, the drug Rajesh Surapaneni prescribed most often to Medicare patients was Revlimid (Lenalidomide), with 100 prescriptions and refills. In total Rajesh Surapaneni wrote 1,171 Medicare prescriptions that cost $6.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | 100 | 100 | 14 | $1.7M |
| Hydroxyurea Generic | 96 | 222 | 25 | $2,248 |
| Dexamethasone Generic | 92 | 100 | 21 | $1,312 |
| Eliquis Apixaban | 72 | 110 | 18 | $62K |
| Prednisone Generic | 56 | 60 | 11 | $402 |
| Abiraterone Acetate Generic | 55 | 55 | Under 11 | $19K |
| Acyclovir Generic | 47 | 87 | 12 | $601 |
| Gabapentin Generic | 41 | 41 | Under 11 | $250 |
| Anastrozole Generic | 40 | 108 | 12 | $1,968 |
| Calquence Acalabrutinib Maleate | 32 | 32 | Under 11 | $462K |
| Imbruvica Ibrutinib | 31 | 31 | Under 11 | $453K |
| Imatinib Mesylate Generic | 29 | 29 | Under 11 | $52K |
| Ninlaro Ixazomib Citrate | 28 | 28 | Under 11 | $346K |
| Brukinsa Zanubrutinib | 25 | 25 | Under 11 | $369K |
| Lenalidomide Generic | 22 | 22 | Under 11 | $195K |
Brand drugs: 492 claims; generic drugs: 679 claims; opioid claims: 17.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Rajesh Surapaneni were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.